prIME Oncology podcasts in hematology and hematologic malignancies http://www.prIMEoncology.org en-us Copyright 2011 Wed, 11 May 2011 11:30:00 -0500 Wed, 11 May 2011 11:30:00 -0500 http://blogs.law.harvard.edu/tech/rss web@oncoservices.com (prIME Oncology Web Administrator) prIME Oncology prIME Oncology virtual learning activities prIME Oncology podcasts in hematology and hematologic malignancies prIME Oncology Web Administrator web@oncoservices.com No http://prIMEoncology.org http://primeoncology.org/podcast/sandiego/mpn/intro-large.mov Introduction with Janice Galleshaw, MD, prIME Oncology Medical Director Podcast Monday, 9 January 2012 11:46:00 -0500 prIME Oncology No Expert Perspectives in Myeloproliferative Neoplasms from the 2011 Annual Hematology Meeting in San Diego Introduction with Janice Galleshaw, MD, prIME Oncology Medical Director 00:01:15 oncology http://prIMEoncology.org http://primeoncology.org/podcast/sandiego/mpn/cervantes-large.mov Francisco Cervantes, MD, PhD, from Hospital Clinic, Barcelona, Spain, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss how to define MPNs, recent changes in the classification system, and risk assessment with the IPSS and dynamic DIPSS. Podcast Monday, 9 January 2012 11:45:00 -0500 prIME Oncology No Expert Perspectives in Myeloproliferative Neoplasms from the 2011 Annual Hematology Meeting in San Diego Francisco Cervantes, MD, PhD, from Hospital Clinic, Barcelona, Spain, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss how to define MPNs, recent changes in the classification system, and risk assessment with the IPSS and dynamic DIPSS. 00:07:18 oncology http://prIMEoncology.org http://primeoncology.org/podcast/sandiego/mpn/harrison-large.mov Claire Harrison, DM, from St Guy's and St Thomas' Trust, London, United Kingdom, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss the only potentially curative therapy for MPNs, allogeneic stem cell transplant (allo-SCT), as well as palliative therapies. Podcast Monday, 9 January 2012 11:44:00 -0500 prIME Oncology No Expert Perspectives in Myeloproliferative Neoplasms from the 2011 Annual Hematology Meeting in San Diego Claire Harrison, DM, from St Guy's and St Thomas' Trust, London, United Kingdom, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss the only potentially curative therapy for MPNs, allogeneic stem cell transplant (allo-SCT), as well as palliative therapies. 00:08:46 oncology http://prIMEoncology.org http://primeoncology.org/podcast/sandiego/mpn/kiladjian-large.mov Jean-Jacques Kiladjian, MD, PhD, from Hôpital Saint-Louis, Paris, France, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss the discovery of the JAK-STAT pathway and the subsequent identification of the activating mutation, JAK[V617F]. Podcast Monday, 9 January 2012 11:43:00 -0500 prIME Oncology No Expert Perspectives in Myeloproliferative Neoplasms from the 2011 Annual Hematology Meeting in San Diego Jean-Jacques Kiladjian, MD, PhD, from Hôpital Saint-Louis, Paris, France, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss the discovery of the JAK-STAT pathway and the subsequent identification of the activating mutation, JAK[V617F]. 00:08:09 oncology http://prIMEoncology.org http://primeoncology.org/podcast/sandiego/mpn/verstovsek-large.mov Srdan Verstovsek, MD, PhD, from University of Texas, M. D. Anderson Cancer Center, Houston, Texas, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, review the abstracts that examined the overall survival in patients with MF treated with ruxolitinb in clinical trials. Podcast Monday, 9 January 2012 11:42:00 -0500 prIME Oncology No Expert Perspectives in Myeloproliferative Neoplasms from the 2011 Annual Hematology Meeting in San Diego Srdan Verstovsek, MD, PhD, from University of Texas, M. D. Anderson Cancer Center, Houston, Texas, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, review the abstracts that examined the overall survival in patients with MF treated with ruxolitinb in clinical trials. 00:06:46 oncology http://prIMEoncology.org http://primeoncology.org/podcast/sandiego/mpn/mesa-large.mov Ruben Mesa, MD, from Mayo Clinic, Scottsdale, Arizona, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, summarize the pivotal phase II trials in myelofibrosis, COMFORT-I and COMFORT-II, with specific attention to the Quality of Life assessment in these trials. Podcast Monday, 9 January 2012 11:41:00 -0500 prIME Oncology No Expert Perspectives in Myeloproliferative Neoplasms from the 2011 Annual Hematology Meeting in San Diego Ruben Mesa, MD, from Mayo Clinic, Scottsdale, Arizona, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, summarize the pivotal phase II trials in myelofibrosis, COMFORT-I and COMFORT-II, with specific attention to the Quality of Life assessment in these trials. 00:06:45 oncology http://prIMEoncology.org http://primeoncology.org/podcast/sandiego/mpn/vannucchi-large.mov Alessandro Vannucchi, MD, PhD, from University of Florence, Florence, Italy, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss therapies currently being studied in clinical trials for treatment of MPNs. Podcast Monday, 9 January 2012 11:40:00 -0500 prIME Oncology No Expert Perspectives in Myeloproliferative Neoplasms from the 2011 Annual Hematology Meeting in San Diego Alessandro Vannucchi, MD, PhD, from University of Florence, Florence, Italy, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss therapies currently being studied in clinical trials for treatment of MPNs. 00:05:36 oncology http://prIMEoncology.org http://primeoncology.org/podcast/sandiego/leukemia/intro-large.mov Introduction with Janice Galleshaw, MD, prIME Oncology Medical Director Podcast Wednesday, 21 December 2011 11:46:00 -0500 prIME Oncology No Expert Perspectives in Leukemia from the 2011 Annual Hematology Meeting in San Diego Introduction with Janice Galleshaw, MD, prIME Oncology Medical Director 00:00:57 oncology http://prIMEoncology.org http://primeoncology.org/podcast/sandiego/leukemia/kantarjian-large.mov Hagop Kantarjian, MD, from the University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss issues in the initial management of chronic-phase chronic myelogenous leukemia. Podcast Wednesday, 21 December 2011 11:45:00 -0500 prIME Oncology No Expert Perspectives in Leukemia from the 2011 Annual Hematology Meeting in San Diego Hagop Kantarjian, MD, from the University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss issues in the initial management of chronic-phase chronic myelogenous leukemia. 00:05:51 oncology http://prIMEoncology.org http://primeoncology.org/podcast/sandiego/leukemia/melo-large.mov Junia V. Melo, MD, PhD, from the Center for Cancer Biology, Adelaide, South Australia, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss maintenance therapy for patients with CP-CML. Podcast Wednesday, 21 December 2011 11:44:00 -0500 prIME Oncology No Expert Perspectives in Leukemia from the 2011 Annual Hematology Meeting in San Diego Junia V. Melo, MD, PhD, from the Center for Cancer Biology, Adelaide, South Australia, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss maintenance therapy for patients with CP-CML. 00:06:37 oncology http://prIMEoncology.org http://primeoncology.org/podcast/sandiego/leukemia/berger-large.mov Jan Burger, MD, PhD, from the M. D. Anderson Cancer Center, Houston, Texas, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss therapy options for patients with chronic lymphocytic leukemia. Podcast Wednesday, 21 December 2011 11:42:00 -0500 prIME Oncology No Expert Perspectives in Leukemia from the 2011 Annual Hematology Meeting in San Diego Jan Burger, MD, PhD, from the M. D. Anderson Cancer Center, Houston, Texas, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss therapy options for patients with chronic lymphocytic leukemia. 00:07:41 oncology http://prIMEoncology.org http://primeoncology.org/podcast/sandiego/leukemia/gribben-large.mov John Gribben, MD, DSc, FRCP, FRCPath, F Med Sci, from Barts and the London School of Medicine, London, United Kingdom, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss the role of molecular profiling in the diagnosis and management of chronic lymphocytic leukemia. Podcast Wednesday, 21 December 2011 11:43:00 -0500 prIME Oncology No Expert Perspectives in Leukemia from the 2011 Annual Hematology Meeting in San Diego John Gribben, MD, DSc, FRCP, FRCPath, F Med Sci, from Barts and the London School of Medicine, London, United Kingdom, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss the role of molecular profiling in the diagnosis and management of chronic lymphocytic leukemia. 00:07:41 oncology http://prIMEoncology.org http://primeoncology.org/podcast/sandiego/leukemia/hoelzer-large.mov Dieter Hoelzer, MD, PhD, from University of Frankfurt, Germany, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss recent progress in the management of adult acute lymphoblastic leukemia. Podcast Wednesday, 21 December 2011 11:41:00 -0500 prIME Oncology No Expert Perspectives in Leukemia from the 2011 Annual Hematology Meeting in San Diego Dieter Hoelzer, MD, PhD, from University of Frankfurt, Germany, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss recent progress in the management of adult acute lymphoblastic leukemia. 00:05:32 oncology http://prIMEoncology.org http://primeoncology.org/podcast/sandiego/leukemia/link-large.mov Daniel Link, MD, from Washington University, St Louis, Missouri, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss genomic sequencing in acute myeloid leukemia. Podcast Wednesday, 21 December 2011 11:40:00 -0500 prIME Oncology No Expert Perspectives in Leukemia from the 2011 Annual Hematology Meeting in San Diego Daniel Link, MD, from Washington University, St Louis, Missouri, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss genomic sequencing in acute myeloid leukemia. 00:04:03 oncology http://prIMEoncology.org http://primeoncology.org/podcast/Lugano/intro.mov Introduction with Janice Galleshaw, MD, prIME Oncology Medical Director Podcast Friday, 08 July 2011 11:40:00 -0500 prIME Oncology No Expert Perspectives from Lugano Introduction with Janice Galleshaw, MD, prIME Oncology Medical Director 00:01:04 oncology http://prIMEoncology.org http://primeoncology.org/podcast/Lugano/armitage.mov James O. Armitage, MD, from the University of Nebraska Medical Center in Omaha, Nebraska, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss personalized therapy for patients with follicular lymphoma. Podcast Friday, 08 July 2011 11:31:00 -0500 prIME Oncology No Expert Perspectives from Lugano James O. Armitage, MD, from the University of Nebraska Medical Center in Omaha, Nebraska, United States, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss personalized therapy for patients with follicular lymphoma. 00:06:53 oncology http://prIMEoncology.org http://primeoncology.org/podcast/Lugano/gisselbrecht.mov Christian Gisselbrecht, MD, from Hospital Saint Louis in Paris, France, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss personalized therapy for patients with mantle cell lymphoma. Podcast Friday, 08 July 2011 11:32:00 -0500 prIME Oncology No Expert Perspectives from Lugano Christian Gisselbrecht, MD, from Hospital Saint Louis in Paris, France, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss personalized therapy for patients with mantle cell lymphoma. 00:03:46 oncology http://prIMEoncology.org http://primeoncology.org/podcast/Lugano/montserrat.mov Emilio Montserrat, MD, from the Hematology and Oncology Hospital Clinic, University of Barcelona, Spain, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss personalized therapy for patients with chronic lymphocytic leukemia. Podcast Friday, 08 July 2011 11:33:00 -0500 prIME Oncology No Expert Perspectives from Lugano Emilio Montserrat, MD, from the Hematology and Oncology Hospital Clinic, University of Barcelona, Spain, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss personalized therapy for patients with chronic lymphocytic lymphoma. 00:05:53 oncology http://prIMEoncology.org http://primeoncology.org/podcast/Lugano/pfreundschuh.mov Michael Pfreundschuh, MD, from the Saarland University Medical School in Homburg, Germany, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss personalized therapy for patients diffuse large B-cell lymphoma. Podcast Friday, 08 July 2011 11:34:00 -0500 prIME Oncology No Expert Perspectives from Lugano Michael Pfreundschuh, MD, from the Saarland University Medical School in Homburg, Germany, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss personalized therapy for patients with diffuse large B-cell lymphoma. 00:05:01 oncology http://prIMEoncology.org http://primeoncology.org/podcast/Lugano/cavalli.mov Franco Cavalli, MD, from the Oncology Institute of Southern Switzerland in Bellinzona, Switzerland and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss personalized therapy for patients with non-Hodgkin lymphoma. Podcast Friday, 08 July 2011 11:34:00 -0500 prIME Oncology No Expert Perspectives from Lugano Franco Cavalli, MD, from the Oncology Institute of Southern Switzerland in Bellinzona, Switzerland and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss personalized therapy for patients with non-Hodgkin lymphoma. 00:05:12 oncology http://prIMEoncology.org http://primeoncology.org/podcast/Lugano/illedge.mov Timothy Illidge, MD, from Christie Hospital in Manchester, United Kingdom, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss the role of radioimmunotherapy in non-Hodgkin lymphoma. Podcast Friday, 08 July 2011 11:34:00 -0500 prIME Oncology No Expert Perspectives from Lugano Timothy Illidge, MD, from Christie Hospital in Manchester, United Kingdom, and Janice Galleshaw, MD, prIME Oncology Medical Director, discuss the role of radioimmunotherapy in non-Hodgkin lymphoma. 00:04:16 oncology